The Innovative Health Initiative (IHI)

Accelerating cross-sectoral discoveries in disease areas with a high burden on patients and society

The new 2.4 billion Euro European Innovative Health Initiative (IHI) aims for more cooperation across sector boundaries. Parties in Pharma, Medtech, BioTech, AI and imaging will work together with patients. Finding the right partners for your IHI proposal can be challenging. With more than 10 years of experience, ttopstart can help you.

IHI challenges

There is an urgent need for an innovative, more integrated approach to health research and healthcare. Future breakthroughs in medical science will involve cross-sectoral discoveries, such as medical device/drug combinations or diagnostics based on artificial intelligence.

The number of participating sector organisations in IHI is, therefore, larger and broader than in IMI. In addition to the main IMI partner EFPIA (European Federation of Pharmaceutical Industries and Associations) new partners Vaccines Europe, COCIR (medical imaging, radiotherapy, health ICT and electromedical industries), EuropaBio (biotechnology industry) and MedTech Europe (medical technology industry) will co-fund the programme.

Need help? Please contact our IHI expert Marc Derieppe.


“ttopstart has more than 12 years of experience in bringing the right partners together, in particular in IMI and this year IHI projects. My advice: start on time, start now!”


How can we help you

We strongly believe in IHI’s strategy to further cross-sectoral innovations, which in the end will have a real and sustainable impact on patient and patient care. But how do you find the right consortium partners in these sectors that are still often isolated? How do you ensure that you are at the right table on time? How do you align your goals with those of others?’  ttopstart has more than 12 years of experience in bringing together partners, in particular in IMI and this year iHI projects.  We developed a set of ‘best practices’ to keep all your consortium partners engaged and focused on the real impact for patients. Have a look at our client stories


The beginning of October, IHI published draft topics, which will help you to start on time to work on your proposal and look for partners.
Single-stage calls:

  • Screening platform & biomarkers for disease prediction
  • Patient-generated evidence for better outcomes
  • Improving outcomes in hospitals
  • Advanced therapies for rare diseases
  • Digital technologies and mental health

Two-stage calls

  •  Non-clinical drug safety assessments
  • Patient-centric blood sample collection

Like IMI, IHI will run open, competitive Calls for proposals. It will continue to publish draft topic texts before the Call launch to give applicants additional time to work on proposals.

Related news

Patient involvement: what is next for IHI?

Patient involvement: what is next for IHI? Four insights on the effective implementation of patient involvement practices in IHI projectsInvolving patients has become essential to effectively accelerate development of better and safer medicines and therapies. Multiple...

Read more

New calls for EU4Health program

New calls for EU4Health programThe European Commission has recently announced the opening of new calls under the EU4Health program which open until October 17, 2023. In this article, we will explore the various calls and their significance in advancing healthcare...

Read more

IHI launches draft topics Call 4 & 5

IHI launches draft topics Call 4 & 5The Innovative Health Initiative (IHI) is gearing up for its next round of calls for proposals, set to launch in the summer of 2023. To provide potential applicants with ample time to prepare, IHI has released draft topic texts...

Read more

Get in touch with us

Thinking about applying for an IHI grant? ttopstart can support you! We have extensive experience and have supported several successful IMI proposals. Contact us today to find out what we can do for you.

    Client stories


    is a multi-national project and aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy.


    aims to improve treatment for patients with cancer through artificial intelligence.


    is an IMI-funded project that aims to set up a sustainable and flexible platform for molecular imaging of immune cell dynamics using a broad range of novel tracer strategies.